Amylin Sees Symlin Playing “Foundational Role” In Obesity Program
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO-to-be Bradbury outlines plans for several obesity studies of pramlintide in combination with marketed and investigational products.